Page 2 - Pharmaceutical Firms

Cough syrup tragedy: SIT arrests wife of accused Dr Praveen Soni

The SIT investigating the cough syrup tragedy that claimed the lives of 24 children in Madhya Pradesh has arrested the wife of accused Dr Praveen Soni, an official said on Tuesday. Chhindwara-based Dr Soni, who allegedly prescribed the contaminated cough syrup 'Coldrif' to most of the ailing kids, was arrested last month for alleged negligence in connection with the child deaths due to kidney failure. His wife Jyoti Soni, another accused in the case, was arrested from her residence in Parasia town of Chhindwara district on Monday night, Sub Divisional Office of Police and Special Investigation Team (SIT) in-charge Jitendra Jaat said. She is the proprietor of a medical shop from where the cough syrup was sold to several victims, the official said. So far, seven persons have been arrested in connection with the cough syrup tragedy, he added. Following the child deaths, the Tamil Nadu government revoked the licence of the cough syrup manufacturing company, Sresan Pharma. Those arres

Pfizer sues to stop rival bid for Metsera by Denmark's Novo Nordisk

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark's Novo Nordisk, over a bid for Metsera that Novo announced Thursday. Novo said it planned to buy Metsera in a deal that could be worth up to $9 billion, and Metsera said the offer appeared to be superior to Pfizer's bid, which was announced in September. Metsera Inc has no products on the market, but it is developing potential oral and injectable treatments. That includes some potential treatments that could target lucrative fields for obesity and diabetes. Novo already has the treatments Wegovy and Ozempic on the market in those respective categories. Pfizer said the offer from Novo cannot be considered superior to its bid because it carries significant regulatory risk that makes it unlikely to be completed. Pfizer, which ended development of a potential pill to

Achin Gupta to succeed Umang Vohra as Cipla MD & GCEO from April 2026

Umang Vohra joined Cipla in 2015 as global chief financial and strategy officer and thereafter served as the company's MD & GCEO since 2016

India's pharma, healthcare deals surge 166% to $3.5 bn in Q3: Report

Grant Thornton Bharat says India's pharma and healthcare sectors saw renewed investor confidence, driven by consolidation across pharma, biotech, and hospital segments

Laurus Labs shares drop 3% despite analysts' bullish outlook; details here

Laurus Labs reported a strong Q2 FY26 performance, with consolidated net profit soaring multifold to ₹194.97 crore, compared with ₹19.78 crore in Q2 FY25

Govt to tighten rules for sale of oral formulations containing alcohol

Health Ministry also mandates QR codes on vaccines and anti-cancer meds, eases sales licence norms for liquid antiseptics

Biocon Biologics expands Civica tie-up to launch pvt-label insulin in US

The move aims to increase the availability of affordable insulin for the country's 38.4 million diabetes patient

Balaji Amines accused of making pharma-grade chemical without licence

Balaji said it had tested its PG using US and Indian pharma standards at the behest of its non-pharma clients, and this was the reason why those standards were mentioned in its PG labels

Tariff relief buzz lifts Nifty Pharma Index; Lupin, Aurobindo lead gains

Pharma stocks were rising in trade today as export concerns eased on US tariff report. Check out the top stocks that may benefit from US tariff relief

Sai Parenteral's files DRHP for IPO, aims to raise ₹285-cr via fresh issue

Sai Parenteral's has filed its DRHP to raise ₹285 crore through a fresh issue and an offer for sale (OFS) of up to 3.5 million shares

Do kids even need cough syrups? Doctors say they may do more harm than good

The recent child deaths in MP and Rajasthan have reignited debate on whether cough syrups are safe or even effective for kids or are they a needless and risky habit?

Indian pharma market grows 7.3% in September, chronic drugs gain traction

India's pharmaceutical market rose 7.3% year-on-year in September to ₹20,886 crore, driven by robust growth in antidiabetic, cardiac, and respiratory therapies

From silica gel to smart sorbents: How pharma packaging is evolving

Loose silica gel packets are being replaced by built-in smart sorbents that block moisture, oxygen, and odour, boosting safety, stability and patient convenience

Lupin to acquire VISUfarma BV for €190 mn to expand European eyecare reach

Lupin's unit Nanomi BV will acquire VISUfarma BV from GHO Capital for €190 mn, adding an eyecare portfolio across Europe and strengthening its ophthalmology franchise

Lupin subsidiary Nanomi BV inks pact to acquire Netherlands-based VISUfarma

Drug maker Lupin on Monday said its subsidiary has inked a pact to fully acquire Amsterdam-headquartered VISUfarma BV at an enterprise value of 190 million euros. The company's wholly-owned subsidiary, Nanomi BV has signed a definitive agreement for the acquisition of VISUfarma BV, a portfolio company of global healthcare specialist investor GHO Capital Partners LLP, the Mumbai-based drug maker said in a statement. The acquisition of VISUfarma, with its broad portfolio of eye health products and established commercial infrastructure, aligns with the company's strategy to expand its European business and footprint and to advance the company's global specialty franchise, it added. By integrating VISUfarma's established commercial operations, Lupin will tap into the attractive ophthalmology market, which is experiencing significant global growth driven by an aging global population, the increasing incidence of diabetes-related eye complications, and growing awareness of preventive care

Trump's new tariffs shake Asian economies still reeling from trade war

On Thursday, Trump announced another round of tariffs, which would go into effect on Oct 1, applying import duties ranging from 25 percent to 100 percent on pharmaceuticals, heavy trucks, etc

Poly Medicure shares jump 5% on plans to acquire Citieffe Group for ₹324-cr

Poly Medicure shares rose 5 per cent after it announced its decision to fully acquire Italy-based Citieffe Group

Indian pharma sector revenue growth to ease to 7-9% in FY26: Crisil

Crisil projects India pharma growth at 7-9% in FY26 as exports to regulated markets slow after a US high base while domestic sales benefit from tax cuts and launches

Laurus Labs soars 6% in 2 days, market cap tops ₹ 50,000 crore; here's why

At 11:29 AM, Laurus Labs' stock was quoting 2 per cent higher at ₹943.15 on the BSE, commanding an m-cap of ₹50,913 crore, exchange data shows

Indian pharma faces US revenue slowdown amid scrutiny, tariffs: ICRA

ICRA projects Indian pharma firms' US revenue growth to slow due to price erosion, USFDA scrutiny and tariff risks, while high dependence on Chinese APIs persists despite PLI